Clinical Trial Update: Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml). [Phase 2]

View source ↗

Summary

A Phase 2 safety trial evaluating two immunotherapy formulations for grass and tree pollen allergies has completed, focusing on allergic rhinitis and related co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Allergic Rhinoconjunctivitis
• Seasonal Allergic Asthma

Drugs mentioned

• Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml) (depigoid)
• Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) (depigopid)

Snippet

Sponsor: Laboratorios Leti, S.L. | Conditions: Allergy, Rhinitis | Phase 2 | Status: COMPLETED